T-Therapeutics I Home
Next generation T cell engagers addressing previously undruggable targets to improve patients’ lives
Scroll Down
Our proprietary suite of best-in-class platform technologies is foundational to our bispecific TCR-CD3 T cell engagers
Our TCR platform, OpTiMus®, can generate an unparalleled repertoire of high specificity, fully human TCRs, enabling access to validated, but previously undruggable, intracellular targets.
Combined with our unique technologies OpTiMus® forms a flexible discovery engine with an integrated workflow from discovery through to candidate generation. Importantly, the platform is modular and can be applied across multiple therapeutic modalities, making it particularly well suited to discovery collaborations.
We select targets that are applicable to a wide range of diseases, yet are highly selective towards pathogenic cells.
Our strategy is to create and develop first-in-class drugs for diseases with high unmet medical need. Our lead programme in oncology has broad potential across multiple different solid tumour types. Our immunology programme is a bispecific designed for precision immune reset, achieved by the selective depletion of pathogenic immune cells.
Platform
From platform to pipeline
T-Therapeutics is developing a pipeline of first-in-class drugs that will become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Pipeline
We combine world-leading expertise in biopharmaceuticals, genomics and biology, anchored in a culture of creativity and collaboration
About
T-Therapeutics
One Granta
Granta Park
Cambridge
CB21 6DP